Shots:

• The clinical study involves assessing VasQ vs SOC in 40 patients in a ratio (1:1) for 6mos. to improve the short and mid-term outcomes of arteriovenous fistulas for hemodialysis
• The clinical study resulted in improvement in functional potency with increased intra-luminal vein diameters in the cannulation segment at 3mos. post fistula creation- the occurrence of fistula failure (15% vs 50%)- patients who required hemodialysis- received it via fistula (100% vs 56%)
• VasQ is a CE marked blood vessel external support device- designed to improve maturation and patency rates of AV fistulas and is available in hospital in Europe & Israel

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Med Gadget